Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
569.15 | 7,075 Cr | 31.89 | 15.15 | 0.79 | 47.50 | 52.11 | 32.88 | ||
215.00 | 6,974 Cr | 4.49 | 5.21 | 0.00 | 116.01 | 80.89 | 71.55 | ||
845.50 | 6,799 Cr | 32.51 | 5.68 | 0.12 | 17.46 | 23.00 | 15.41 | ||
417.80 | 6,794 Cr | 24.14 | 2.73 | 1.20 | 11.32 | 15.18 | 9.64 | ||
1411.50 | 6,500 Cr | 56.34 | 6.96 | 0.00 | 12.36 | 14.43 | 7.58 | ||
685.65 | 6,217 Cr | 33.34 | 2.93 | 0.51 | 8.22 | 9.59 | 5.36 | ||
975.00 | 5,527 Cr | 39.22 | 5.07 | 0.21 | 12.92 | 14.30 | 7.67 | ||
| Median: 7 Co. | — | 685.65 | 6,794 Cr | 32.51 | 5.21 | 0.21 | 12.92 | 15.18 | 9.64 |
Aarti Pharmalabs Ltd (AARTIPHARM) is currently trading at 680.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aarti Pharmalabs is a vertically integrated Indian manufacturer of generic APIs, intermediates, HPAPIs and xanthine derivatives, and a growing small-molecule CDMO/CMO provider with three USFDA-approved units, seven manufacturing sites and a focus on regulated markets across the USA, EU, Japan and ROW. Aarti Pharmalabs is the largest Indian manufacturer of Xanthine derivatives with ~15–20% global share today and is building incremental capacity from 5,000 to 9,000 MTPA at Tarapur to target 20–25% global share, leveraging a China+1 tailwind and multiple beverage and pharma customer contracts. The CDMO/CMO vertical is a strategic growth lever: 21 customers and 59 active projects (40 commercial), CDMO revenue rose from INR 208 crore in FY25 and management targets 30–40% growth for FY26E, while Atali greenfield is designed to materially increase intermediates and CDMO throughput. Financials show resilience but near-term stress: 9M-FY26 standalone revenue INR 12,179 million (down 1.9% Y/Y), EBITDA margin ~22%, PAT down materially due to higher depreciation and finance costs from capex; net debt/equity rose to ~0.26x in H1-FY26 as expansion spending accelerated. The company pairs R&D and sustainability credentials—three R&D centres, 116 process scientists, 62 patents filed and ecovadis GOLD plus CDP engagement and renewable projects (21 MW solar) intended to supply roughly half of power needs and reduce operating costs and carbon footprint.
Over the past 52 weeks, Aarti Pharmalabs Ltd has traded between a low of ₹583.85 and a high of ₹952.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aarti Pharmalabs Ltd has a market capitalization of approximately 6,217.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aarti Pharmalabs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 33.34 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6,217.46 Cr, Aarti Pharmalabs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aarti Pharmalabs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aarti Pharmalabs Ltd is 33.34. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Aarti Pharmalabs is a vertically integrated Indian manufacturer of generic APIs, intermediates, HPAPIs and xanthine derivatives, and a growing small-molecule CDMO/CMO provider with three USFDA-approved units, seven manufacturing sites and a focus on regulated markets across the USA, EU, Japan and ROW.
Aarti Pharmalabs is the largest Indian manufacturer of Xanthine derivatives with ~15–20% global share today and is building incremental capacity from 5,000 to 9,000 MTPA at Tarapur to target 20–25% global share, leveraging a China+1 tailwind and multiple beverage and pharma customer contracts.
The CDMO/CMO vertical is a strategic growth lever: 21 customers and 59 active projects (40 commercial), CDMO revenue rose from INR 208 crore in FY25 and management targets 30–40% growth for FY26E, while Atali greenfield is designed to materially increase intermediates and CDMO throughput.
Financials show resilience but near-term stress: 9M-FY26 standalone revenue INR 12,179 million (down 1.9% Y/Y), EBITDA margin ~22%, PAT down materially due to higher depreciation and finance costs from capex; net debt/equity rose to ~0.26x in H1-FY26 as expansion spending accelerated.
The company pairs R&D and sustainability credentials—three R&D centres, 116 process scientists, 62 patents filed and ecovadis GOLD plus CDP engagement and renewable projects (21 MW solar) intended to supply roughly half of power needs and reduce operating costs and carbon footprint.
Pharmaceuticals & Biotechnology
Pharmaceuticals
6,174 Cr
High Risk
33.1
37.2
2.8
2.9
952.00
583.85
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
4
Neutral
8
Bullish
2
Bearish
29
Neutral
8
Bullish
9
Bearish
25
Neutral
0
Bullish
7
